TY - JOUR
T1 - Ontogeny of opioid and related peptides in the rat CNS and pituitary
T2 - An immunocytochemical study
AU - Khachaturian, Henry
AU - Alessi, Norman E.
AU - Munfakh, Nabil
AU - Watson, Stanley J.
N1 - Funding Information:
This work was supported by NIMH training grant MH15794 to HK Grant MH36851 to SJW.
PY - 1983
Y1 - 1983
N2 - The development of proopiomelanocortin (POMC) derived peptides was compared to that of leucine-enkephalin ([Leu]ENK) and dynorphin A (DYN-A) immunoreactivity (i.r.) in the rat CNS and pituitary gland. POMC i.r. appeared first in hypothalamic neurons on embryonic day E12, in pituitary anterior lobe (AL) cells on E15, in pituitary intermediate lobe (IL) cells on E16, and in perikarya of the nucleus tractus solitarius on E17. In the fetal stages (E19-22), all POMC systems appeared adult-like; however, peak i.r. occurred between postnatal days P21-28. The development of alpha-MSH (a-MSH) i.r. was dissimilar to that of other POMC peptides including beta-endorphin (B-End). In contrast, both [Leu]ENK and DYN-A i.r. appeared in later embryonic stages (E16-17), and their maturation lagged behind that of POMC peptides. Peak i.r. for these latter peptides also occurred between P21-28.
AB - The development of proopiomelanocortin (POMC) derived peptides was compared to that of leucine-enkephalin ([Leu]ENK) and dynorphin A (DYN-A) immunoreactivity (i.r.) in the rat CNS and pituitary gland. POMC i.r. appeared first in hypothalamic neurons on embryonic day E12, in pituitary anterior lobe (AL) cells on E15, in pituitary intermediate lobe (IL) cells on E16, and in perikarya of the nucleus tractus solitarius on E17. In the fetal stages (E19-22), all POMC systems appeared adult-like; however, peak i.r. occurred between postnatal days P21-28. The development of alpha-MSH (a-MSH) i.r. was dissimilar to that of other POMC peptides including beta-endorphin (B-End). In contrast, both [Leu]ENK and DYN-A i.r. appeared in later embryonic stages (E16-17), and their maturation lagged behind that of POMC peptides. Peak i.r. for these latter peptides also occurred between P21-28.
UR - http://www.scopus.com/inward/record.url?scp=0021054039&partnerID=8YFLogxK
U2 - 10.1016/0024-3205(83)90444-7
DO - 10.1016/0024-3205(83)90444-7
M3 - Article
C2 - 6141503
AN - SCOPUS:0021054039
SN - 0024-3205
VL - 33
SP - 61
EP - 64
JO - Life Sciences
JF - Life Sciences
IS - SUPPL. 1
ER -